SASP Gradient Zonation Determines Stem Cell Fate via ECM-Modulated Diffusion Thresholds

Hypothesis

Senescent cells secrete SASP factors that form concentration gradients shaped by extracellular matrix heparan sulfate proteoglycans, creating distinct zones: a proximal high‑SASP zone that enforces stem cell quiescence and a distal low‑SASP zone that permits regeneration. The transition point is defined by a threshold concentration at which downstream signaling switches from p21‑mediated cell‑cycle arrest to AKT‑driven proliferation.

Mechanistic Basis

Recent spatial observations show γδ T cells and senescent cell ligands colocalize in IPF lung [Spatial colocalization of γδ T cells and senescent cell ligands in IPF lung] and senescent cells accumulate in fibro‑adipogenic progenitor niches of aged muscle [Senescent cells accumulate in fibro‑adipogenic progenitor niches in aged muscle]. These data imply localized secretory effects but lack quantitative decay measurements. Heparan sulfate proteoglycans (HSPGs) are known to bind chemokines such as CXCL8 and IL‑6, effectively acting as sinks that steepen gradient slopes [Heparan sulfate modulation of cytokine gradients]. In young tissue, lower HSPG density yields longer SASP reach, allowing low‑dose SASP to stimulate progenitor proliferation via JAK/STAT. In aged tissue, upregulated HSPG expression compresses the SASP field, pushing more cells into the high‑dose zone where SASP triggers p53/p21‑mediated arrest or apoptosis.

Predictions

1. In aged mouse muscle, the SASP mRNA gradient from p16^INK4a^+ cells will fit an exponential decay with a shorter length constant (λ) than in young muscle.
2. The distance at which SASP‑induced p21 expression falls below 20 % of its maximal value will correlate inversely with local HSPG staining intensity.
3. Stem‑cell proliferation (Ki67^+ Pax7^+ cells) will peak at distances where SASP concentration is between 10‑30 % of the peak, and decline both closer (quiescence) and farther (baseline) from senescent foci.
4. Enzymatic removal of heparan sulfate (heparinase III treatment) will lengthen λ and shift the proliferative zone outward, rescuing regeneration in aged muscle.

Experimental Design

• Generate p16^INK4a‑Cherry reporter mice; isolate young (3 mo) and aged (24 mo) tibialis anterior muscles.
• Perform Slide‑seqV2 (or Visium) to obtain transcript counts; identify senescent cells by Cherry^+ and p16^INK4a^high mRNA.
• Quantify SASP transcripts (Il6, Cxcl1, MMP3, SERPINE1) per spot; fit radial exponential decay functions around each senescent spot to estimate λ.
• Co‑stain sections for heparan sulfate (HS) using anti‑HS antibody; measure HS intensity per spot.
• Assess stem‑cell state: Pax7, MyoD, Ki67, p21 immunofluorescence; compute proliferation index as function of distance from senescent foci.
• In a subset, inject heparinase III into aged muscle; repeat spatial transcriptomics and proliferation readouts.
• Statistical comparison: linear regression of λ vs HS intensity; SASP concentration thresholds for p21 vs Ki67 using ROC analysis.

Potential Outcomes

• If λ shortens with age and correlates positively with HS, the ECM‑sink model is supported.
• If proliferative peak occurs at the predicted low‑dose SASP window and shifts outward after heparinase treatment, the threshold‑dependent fate switch is validated.
• Failure to observe distance‑dependent changes in p21 or Ki67, or lack of HSPG correlation, would falsify the hypothesis, indicating that SASP gradients are either uniform or overridden by other niche signals.